Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Nucl Med Biol. 2013 Oct;40(7):879-86. doi: 10.1016/j.nucmedbio.2013.06.001. Epub 2013 Jul 12.

Characterization of FlipIDAM as a SERT-selective SPECT imaging agent.

Author information

  • 1Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104.

Abstract

INTRODUCTION:

Biological evaluation of ([(125)I]4), a new single-photon emission computed tomography (SPECT) radioligand for imaging the serotonin transporter (SERT) which displayed improved in vivo kinetics for mapping SERT binding sites in the brain.

METHODS:

In vitro binding studies of [(125)I]4 were performed with membrane homogenates of LLC-PK1 cells stably transfected and overexpressing one of the monoamine transporter (SERT, DAT or NET) and rat cortical homogenates. Biodistribution and ex vivo autoradiography studies were carried out in rats. In vivo competition experiments were evaluated to determine the SERT selectivity of [(125)I]4 vs. ([(125)I]1).

RESULTS:

In vitro binding studies of 4 showed excellent binding affinity (Ki,SERT=0.90 ± 0.05 nM) and excellent selectivity over the other monoamine transporters (100 fold and >4000 fold for NET and DAT respectively). Scatchard analysis of saturation binding of [(125)I]4 to rat cortical homogenates gave a Kd value of 0.5 ± 0.09 nM and a Bmax value of 801.4 ± 58.08 fmol/mg protein. The biodistribution study showed rapid high brain uptake (3.09 ± 0.11% dose/organ at 2 min) and a good target to non-target ratio (hypothalamus to cerebellum) at 30 min (2.62) compared to [(125)I]1 (2.19). Ex vivo autoradiography showed that FlipIDAM localizes in accordance with SERT distribution patterns in the brain. In vivo and ex vivo competition experiments with specific and non-specific SERT compounds also showed that [(125)I]4 binds specifically to SERT rich regions.

CONCLUSIONS:

The biological evaluation of [(125)I]4 demonstrates that [(123)I]4 would be a good candidate for SPECT imaging of SERT.

Copyright © 2013. Published by Elsevier Inc.

KEYWORDS:

(+)-McN5652; (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol); (5-iodo-2-((2-((dimethylamino)methyl)phenyl)thio)benzyl alcohol); (N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine); 2-((2-((dimethylamino)methyl)-phenyl)thio)-5-iodophenylamine; 2-(2'-((dimethylamino)methyl)-4'-iodophenylthio)benzenamine; 2<beta>-carbomethoxy-3<beta>-(4-iodophenyl); 2<beta>-carbomethoxy-3<beta>-(4-iodophenyl)tropane; 5-HT; 5-HTT; <beta>-CIT; ADAM (2); Brain imaging; DASB; FlipADAM (3); FlipIDAM (4); IACUC; IDAM (1); Institutional Animal Care and Use Committee; MADAM; N,N-dimethyl-2-(2-amino-4-methylphenylthio)benzylamine; Radioligand; SERT; SPECT; SSRI; St; Th; nor-<beta>-CIT; selective serotonin reuptake inhibitor; serotonin; serotonin transporter; single photon emission computed tomography; striatum; thalamus; trans-1,2,3,5,6,10-<beta>-hexahydro-6-[4-(methylthio)phenyl-[pyrrolo-[2,1-<alpha>]isoquinoline

PMID:
23856117
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk